Related Experiment Videos
[Lipid lowering therapy: new pathophysiologic aspects and clinical implications]
A Nordmann1, B Martina, U Keller
1Medizinische Universitäts-Poliklinik, Kantonsspital Basel.
Insights
Lipid-lowering therapy offers cardiovascular benefits beyond plaque size reduction. It improves endothelial function and other factors, contributing to reduced cardiovascular risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Lipid-lowering therapy is crucial for reducing cardiovascular morbidity and mortality.
- While plaque regression is observed, it doesn't fully account for clinical benefits.
Purpose:
- To explore mechanisms of lipid-lowering therapy beyond plaque size reduction.
- To highlight the role of endothelial function in cardiovascular disease.
Summary:
- Lipid-lowering therapy induces qualitative plaque composition changes, potentially reducing rupture risk.
- It reverses endothelial dysfunction, improving vasodilation and reducing adhesion molecules.
- Therapy may also decrease peripheral resistance, hyperinsulinemia, and improve erythrocyte deformability.
Impact:
- Endothelial dysfunction is an early, reversible sign of target organ damage.
- Understanding these mechanisms can refine cardiovascular disease diagnosis and treatment.
- These findings emphasize a broader therapeutic impact of lipid management.
Abstract:
Lipid-lowering therapy reduces cardiovascular morbidity and mortality. Although atherosclerotic plaques regress under lipid-lowering therapy, only minor changes in arteriosclerotic plaques are angiographically detectable. These changes cannot fully explain all the benefits of lipid-lowering therapy. Additional factors independent of macroscopically detectable alterations in plaque size may contribute to the clinical effects of lipid-lowering therapy. Qualitative changes in the composition of atherosclerotic plaques may reduce the risk of subsequent plaque rupture. Furthermore, hypercholesterolemia is associated with endothelial dysfunction, i.e., impaired endothelium-mediated vasodilation, induction of adhesion molecules, and altered expression of growth factors. Lipid lowering seems to reverse endothelial dysfunction. Also, lipid-lowering therapy may reduce peripheral arterial resistance and hyperinsulinemia, and may improve erythrocyte deformability. These effects of lipid-lowering therapy may contribute to the clinical benefits. In particular, the concept of endothelial dysfunction as a first, reversible manifestation of target organ damage deserves further attention in the diagnosis and therapy of cardiovascular disease.